Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity

Nature Communications

Volumn 5, Issue , 2014, Pages

  Pernet, Erwan ^a,b,c   Guillemot, Laurent ^a,b   Burgel, Pierre Régis ^d,e   Martin, Clémence ^d,e   Lambeau, Gérard ^f   Sermet Gaudelus, Isabelle ^b   Sands, Dorota ^g   Leduc, Dominique ^a,b   Morand, Philippe C ^d,e   Jeammet, Louise ^f   Chignard, Michel ^a,b   Wu, Yongzheng ^a,b   Touqui, Lhousseine ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e AP HP ^*  (France)

^f CNRS   (France)

^g INSTITUTE OF MOTHER AND CHILD   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPASE A2 TYPE IIA; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG; BACTERIAL TOXIN; EXOENZYME S; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHOLIPASE A2 GROUP II; PLA2G2A PROTEIN, HUMAN;

BACTERIUM; COLONIZATION; ENZYME ACTIVITY; HOST; INFECTIVITY; ISOLATED POPULATION; REMOVAL EXPERIMENT;

ADULT; AIRWAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CONTROLLED STUDY; CYSTIC FIBROSIS; EPITHELIUM CELL; GROWTH INHIBITION; HOST; HOST CELL; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; LABORATORY TEST; LUNG CLEARANCE; LUNG INFECTION; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; ADOLESCENT; ANIMAL; BRONCHUS; CHILD; DISEASE COURSE; ENZYMOLOGY; GUINEA PIG; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; RESPIRATORY TRACT MUCOSA; SPUTUM; YOUNG ADULT;

ANIMALIA; BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADP RIBOSE TRANSFERASES; ADULT; ANIMALS; BACTERIAL TOXINS; BRONCHI; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DISEASE PROGRESSION; EPITHELIAL CELLS; GROUP II PHOSPHOLIPASES A2; GUINEA PIGS; HUMANS; MICE; PSEUDOMONAS AERUGINOSA; RESPIRATORY MUCOSA; SPUTUM; STAPHYLOCOCCUS AUREUS; YOUNG ADULT;

EID: 84923273698     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6105     Document Type: Article

References (70)

1. Cohen-Cymberknoh, M., Shoseyov, D. & Kerem, E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am. J. Respir. Crit. Care Med. 183, 1463-1471 (2011).
2. Lipuma, J. J. The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 23, 299-323 (2010).
3. Kerem, B. et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245, 1073-1080 (1989).
4. Riordan, J. R. et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066-1073 (1989).
5. Bobadilla, J. L., Macek, Jr M., Fine, J. P. & Farrell, P. M. Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum. Mutat. 19, 575-606 (2002).
6. Cohen, T. S. & Prince, A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat. Med. 18, 509-519 (2012).
7. George, A. M., Jones, P. M. & Middleton, P. G. Cystic fibrosis infections: treatment strategies and prospects. FEMS Microbiol. Lett. 300, 153-164 (2009).
8. Hauser, A. R., Jain, M., Bar-Meir, M. & McColley, S. A. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin. Microbiol. Rev. 24, 29-70 (2011).
9. Pressler, T. et al. Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J. Cyst. Fibros. 10(Suppl 2): S75-S78 (2011).
10. Armstrong, D. S. et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 156, 1197-1204 (1997).
11. Harrison, F. Microbial ecology of the cystic fibrosis lung. Microbiology 153, 917-923 (2007).
12. Razvi, S. et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 136, 1554-1560 (2009).
13. Folkesson, A. et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat. Rev. Microbiol. 10, 841-851 (2012).
14. Nevalainen, T. J., Graham, G. G. & Scott, K. F. Antibacterial actions of secreted phospholipases A2. Review. Biochim. Biophys. Acta 1781, 1-9 (2008).
15. Touqui, L. & Alaoui-El-Azher, M. Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr. Mol. Med. 1, 739-754 (2001).
16. Lehrer, R. I. Primate defensins. Nat. Rev. Microbiol. 2, 727-738 (2004).
17. Wu, Y. et al. Type-IIA secreted phospholipase A2 is an endogenous antibioticlike protein of the host. Biochimie 92, 583-587 (2010).
18. Murakami, M. et al. Recent progress in phospholipase A(2) research: from cells to animals to humans. Prog. Lipid Res. 50, 152-192 (2011).
19. Piris-Gimenez, A. et al. In vivo protective role of human group IIa phospholipase A2 against experimental anthrax. J. Immunol. 175, 6786-6791 (2005).
20. Foreman-Wykert, A. K., Weinrauch, Y., Elsbach, P. & Weiss, J. Cell-wall determinants of the bactericidal action of group IIA phospholipase A2 against Gram-positive bacteria. J. Clin. Invest. 103, 715-721 (1999).
21. Qu, X. D. & Lehrer, R. I. Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears. Infect. Immun. 66, 2791-2797 (1998).
22. Oslund, R. C. & Gelb, M. H. Biochemical characterization of selective inhibitors of human group IIA secreted phospholipase A(2) and hyaluronic acid-linked inhibitor conjugates. Biochemistry 51, 8617-8626 (2012).
23. Movert, E. et al. Secreted group IIA phospholipase A2 protects humans against the group B streptococcus: experimental and clinical evidence. J. Infect. Dis. 208, 2025-2035 (2013).
24. Nevalainen, T. J. et al. Time-resolved fluoroimmunoassays of the complete set of secreted phospholipases A2 in human serum. Biochim. Biophys. Acta 1733, 210-223 (2005).
25. Grass, D. S. et al. Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J. Clin. Invest. 97, 2233-2241 (1996).
26. Eerola, L. I. et al. Analysis of expression of secreted phospholipases A2 in mouse tissues at protein and mRNA levels. Biochim. Biophys. Acta 1761, 745-756 (2006).
27. Arbibe, L. et al. Endotoxin induces expression of type II phospholipase A2 in macrophages during acute lung injury in guinea pigs: involvement of TNFalpha in lipopolysaccharide-induced type II phospholipase A2 synthesis. J. Immunol. 159, 391-400 (1997).
28. Zeitlin, P. L. et al. A cystic fibrosis bronchial epithelial cell line: immortalization by adeno-12-SV40 infection. Am. J. Respir. Cell Mol. Biol. 4, 313-319 (1991).
29. Lee, V. T., Smith, R. S., Tummler, B. & Lory, S. Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection. Infect. Immun. 73, 1695-1705 (2005).
30. Hauser, A. R. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat. Rev. Microbiol. 7, 654-665 (2009).
31. Rocha, C. L., Coburn, J., Rucks, E. A. & Olson, J. C. Characterization of Pseudomonas aeruginosa exoenzyme S as a bifunctional enzyme in J774A.1 macrophages. Infect. Immun. 71, 5296-5305 (2003).
32. O'Grady, E. P., Mulcahy, H., O'Callaghan, J., Adams, C. & O'Gara, F. Pseudomonas aeruginosa infection of airway epithelial cells modulates expression of Kruppel-like factors 2 and 6 via RsmA-mediated regulation of type III exoenzymes S and Y. Infect. Immun. 74, 5893-5902 (2006).
33. Hoffman, L. R. et al. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc. Natl Acad. Sci. USA 103, 19890-19895 (2006).
34. Machan, Z. A. et al. Interaction between Pseudomonas aeruginosa and Staphylococcus aureus: description of an anti-staphylococcal substance. J. Med. Microbiol. 34, 213-217 (1991).
35. Mashburn, L. M., Jett, A. M., Akins, D. R. & Whiteley, M. Staphylococcus aureus serves as an iron source for Pseudomonas aeruginosa during in vivo coculture. J. Bacteriol. 187, 554-566 (2005).
36. Yang, L. et al. Pattern differentiation in co-culture biofilms formed by Staphylococcus aureus and Pseudomonas aeruginosa. FEMS Immunol. Med. Microbiol. 62, 339-347 (2011).
37. Nevalainen, T. J., Haapamaki, M. M. & Gronroos, J. M. Roles of secretory phospholipases A(2) in inflammatory diseases and trauma. Biochim. Biophys. Acta 1488, 83-90 (2000).
38. Dubouix, A. et al. Bactericidal properties of group IIa secreted phospholipase A(2) against Pseudomonas aeruginosa clinical isolates. J. Med. Microbiol. 52, 1039-1045 (2003).
39. Koprivnjak, T., Weidenmaier, C., Peschel, A. & Weiss, J. P. Wall teichoic acid deficiency in Staphylococcus aureus confers selective resistance to mammalian group IIA phospholipase A(2) and human beta-defensin. 3. Infect. Immun. 76, 2169-2176 (2008).
40. Rosenthal, M. D. et al. Human neutrophils store type II 14-kDa phospholipase A2 in granules and secrete active enzyme in response to soluble stimuli. Biochem. Biophys. Res. Commun. 208, 650-656 (1995).
41. Madsen, L. M., Inada, M. & Weiss, J. Determinants of activation by complement of group II phospholipase A2 acting against Escherichia coli. Infect. Immun. 64, 2425-2430 (1996).
42. Medjane, S., Raymond, B., Wu, Y. & Touqui, L. Impact of CFTR DeltaF508 mutation on prostaglandin E2 production and type IIA phospholipase A2 expression by pulmonary epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol 289, L816-L824 (2005).
43. Engel, J. & Balachandran, P. Role of Pseudomonas aeruginosa type III effectors in disease. Curr. Opin. Microbiol. 12, 61-66 (2009).
44. Dacheux, D. et al. Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils. Infect. Immun. 68, 2916-2924 (2000).
45. Roy-Burman, A. et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J. Infect. Dis. 183, 1767-1774 (2001).
46. McConnell, B. B. & Yang, V. W. Mammalian Kruppel-like factors in health and diseases. Physiol. Rev. 90, 1337-1381 (2010).
47. SenBanerjee, S. et al. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J. Exp. Med. 199, 1305-1315 (2004).
48. Das, H. et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc. Natl Acad. Sci. USA 103, 6653-6658 (2006).
49. Saavedra, M. T. et al. Abrogation of anti-inflammatory transcription factor LKLF in neutrophil-dominated airways. Am. J. Respir. Cell Mol. Biol. 38, 679-688 (2008).
50. Dach, K. et al. Bacterial toxins induce sustained mRNA expression of the silencing transcription factor klf2 via inactivation of RhoA and Rhophilin. 1. Infect. Immun. 77, 5583-5592 (2009).
51. Zahlten, J. et al. TLR2-and nucleotide-binding oligomerization domain 2-dependent Kruppel-like factor 2 expression downregulates NF-kappa B-related gene expression. J. Immunol. 185, 597-604 (2010).
52. Goehring, U. M., Schmidt, G., Pederson, K. J., Aktories, K. & Barbieri, J. T. The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPaseactivating protein for Rho GTPases. J. Biol. Chem. 274, 36369-36372 (1999).
53. Gimenez, A. P. et al. High bactericidal efficiency of type iia phospholipase A2 against Bacillus anthracis and inhibition of its secretion by the lethal toxin. J. Immunol. 173, 521-530 (2004).
54. Gronroos, J. O., Laine, V. J. & Nevalainen, T. J. Bactericidal group IIA phospholipase A2 in serum of patients with bacterial infections. J. Infect. Dis. 185, 1767-1772 (2002).
55. Movert, E., Wu, Y., Lambeau, G., Touqui, L. & Areschoug, T. A novel bacterial resistance mechanism against human group IIA-secreted phospholipase A2: role of Streptococcus pyogenes sortase A. J. Immunol. 187, 6437-6446 (2011).
56. Harwig, S. S. et al. Bactericidal properties of murine intestinal phospholipase A2. J. Clin. Invest. 95, 603-610 (1995).
57. Weiner, D. J., Bucki, R. & Janmey, P. A. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am. J. Respir. Cell. Mol. Biol. 28, 738-745 (2003).
58. Chen, C. I., Schaller-Bals, S., Paul, K. P., Wahn, U. & Bals, R. Beta-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J. Cyst. Fibros. 3, 45-50 (2004).
59. Pezzulo, A. A. et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487, 109-113 (2012).
60. Berthelot, P. et al. Genotypic and phenotypic analysis of type III secretion system in a cohort of Pseudomonas aeruginosa bacteremia isolates: evidence for a possible association between O serotypes and exo genes. J. Infect. Dis. 188, 512-518 (2003).
61. Delic-Attree, I., Toussaint, B., Froger, A., Willison, J. C. & Vignais, P. M. Isolation of an IHF-deficient mutant of a Pseudomonas aeruginosa mucoid isolate and evaluation of the role of IHF in algD gene expression. Microbiology 142(Pt 10): 2785-2793 (1996).
62. Ramphal, R. et al. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J. Immunol. 181, 586-592 (2008).
63. Kennedy, B. P. et al. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem. 270, 22378-22385 (1995).
64. Buff, S. M. et al. IL-10 delivery by AAV5 vector attenuates inflammation in mice with Pseudomonas pneumonia. Gene Ther. 17, 567-576 (2010).
65. Vasconcellos, C. A. et al. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 263, 969-971 (1994).
66. Brandt, T., Breitenstein, S., von der Hardt, H. & Tummler, B. DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase. Thorax 50, 880-882 (1995).
67. Weiss, J., Franson, C., Schmeidler, K. & Elsbach, P. Reversible envelope effects during and after killing of Escherichia coli w by a highly-purified rabbit polymorpho-nuclear leukocyte fraction. Biochim. Biophys. Acta 436, 154-169 (1976).
68. Paya, M., Terencio, M. C., Ferrandiz, M. L. & Alcaraz, M. J. Involvement of secretory phospholipase A2 activity in the zymosan rat air pouch model of inflammation. Br. J. Pharmacol. 117, 1773-1779 (1996).
69. Burgel, P. R., Cardell, L. O., Ueki, I. F. & Nadel, J. A. Intranasal steroids decrease eosinophils but not mucin expression in nasal polyps. Eur. Respir. J. 24, 594-600 (2004).
70. Martin, C. et al. CFTR dysfunction induces vascular endothelial growth factor synthesis in airway epithelium. Eur. Respir. J. 42, 1553-1562 (2013).